News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
ErgoMed Signs Co-Development Deal With CeNeS Pharmaceuticals PLC
July 13, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ergomed today announced that it has signed a co-development deal with CeNeS Pharmaceuticals to take CNS5161, a novel NMDA antagonist, into a Phase II trial programme for neuropathic pain. Terms of the deal were not disclosed.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Obesity
Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III
July 15, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
July 14, 2025
·
1 min read
·
Dan Samorodnitsky
Layoff Tracker
Massachusetts-Based Karyopharm, Azurity Cut Workforces
July 14, 2025
·
158 min read
·
BioSpace Editorial Staff